Vaxcyte, Inc.
PCVX
$31.16
-$0.29-0.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 32.66M | 28.56M | 22.99M | 21.47M | 19.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 180.79M | 162.17M | 139.92M | 152.98M | 114.47M |
| Operating Income | -180.79M | -162.17M | -139.92M | -152.98M | -114.47M |
| Income Before Tax | -140.72M | -137.08M | -103.12M | -128.70M | -95.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -140.72M | -137.08M | -103.12M | -128.70M | -95.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -140.72M | -137.08M | -103.12M | -128.70M | -95.02M |
| EBIT | -180.79M | -162.17M | -139.92M | -152.98M | -114.47M |
| EBITDA | -177.84M | -159.31M | -138.14M | -151.63M | -113.47M |
| EPS Basic | -1.04 | -1.01 | -0.83 | -1.10 | -0.85 |
| Normalized Basic EPS | -0.65 | -0.63 | -0.52 | -0.69 | -0.53 |
| EPS Diluted | -1.04 | -1.01 | -0.83 | -1.10 | -0.85 |
| Normalized Diluted EPS | -0.65 | -0.63 | -0.52 | -0.69 | -0.53 |
| Average Basic Shares Outstanding | 135.69M | 135.20M | 123.69M | 117.26M | 111.69M |
| Average Diluted Shares Outstanding | 135.69M | 135.20M | 123.69M | 117.26M | 111.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |